Major Addition at Argentina Facility Solidifies Company's Regional
Rochester, New York, (ots-PRNewswire) - Genencor International,
Inc. (Nasdaq: GCOR) announced today it has expanded its business
capabilities in Latin America with the recent opening of its US$6
million coater for the manufacture of granulated enzymes at its
Arroyito, Argentina facility. The increased capacity will allow
Genencor to extend its full-service support of the cleaning, textile,
grain and specialties markets to customers throughout the region.
The company estimates the installation of its coater will triple
the site's granular enzyme production capacity and position Genencor
to capture a larger share of the $150-$200 million enzyme market in
the region. Currently, Genencor's sales in Latin America are growing
at 20 percent annually.
In addition to Genencor's increased regional manufacturing
capacity, the company also offers sales, marketing, technical and
customer service. "We believe Latin America's expanding economy,
large population and rich source of raw materials continue to make it
an important market for us," said Tom Pekich, group vice president,
Industrial Chemicals for Genencor. "In particular, granulated
cleaning products are a significant regional business focus for us
and by offering a full portfolio of services, we can address
customers' needs quickly and efficiently."
The company acquired its Arroyito facility in 1996 through the
purchase of the Solvay worldwide enzyme business. Since that time,
the company has used the facility to produce products primarily for
the cleaning business.
With approximately 100 employees at Genencor facilities in Latin
America, the regional headquarters is located in Buenos Aires with
sales support in Sao Paulo, Brazil and Mexico City, Mexico.
Additionally, Genencor operates eight manufacturing sites around the
world and has sales and marketing headquarters for Europe and Africa
in Leiden, the Netherlands and Asia Pacific in Singapore.
Genencor International is a diversified biotechnology company that
develops and delivers innovative products into the health care,
agriculture, industrial and consumer markets. Using an integrated set
of technology platforms, Genencor's products deliver innovative and
sustainable solutions to many of the problems of everyday life.
Genencor was established in 1982 as a joint venture between
Genentech Inc. and Corning Incorporated. Since its founding, Genencor
has grown to become a leading biotechnology company, with over $315
million in annual revenues, more than 250 biotechnology products in
commerce, and over 3,400 owned and licensed patents and applications.
Genencor, with more than 1,500 employees worldwide, has principal
offices in Palo Alto, California; Rochester, New York; and Leiden,
Except for the historical information contained herein, the
matters discussed in this press release may contain forward-looking
statements which involve risks and uncertainties, including
significant fluctuations in product performance depending on factors
such as a dependence on the efforts of third parties, a new and
uncertain technology employed by Genencor and its uncertain
application to new business ventures, dependence on intellectual
property rights, the competitive nature of Genencor's industry and
risks of obsolescence of certain technology. Actual results may
differ materially from those projected. Forward-looking statements
represent the judgment of Genencor as of the date of this release.
Genencor disclaims, however, any intent or obligation to update any
Make your opinion count - Click Here
ots Originaltext: Genecor International Inc.
Investors: Amy Giller, phone +1 650-846-7500
Media: Angie Blackwell, phone +1 716-256-5200, both of Genencor